Isis Pharmaceuticals (Nasdaq: ISIS) reported positive interim results from an open-label, multiple dose study of ISIS-SMN(Rx) in children with spinal muscular atrophy sending the stock price soaring $7.93 to close at $59.00.
Isis Reports Upbeat Interim Results
February 21, 2014 at 16:29 PM EST
